We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu
IMPORTANT: Due to the lapse in government funding, the information on this web site may not be up to date, transactions submitted via the web site may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

ALX-0171 Phase I Study, Evaluating Single Ascending Dose and Multiple Dose in Healthy Male Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01483911
Recruitment Status : Completed
First Posted : December 2, 2011
Last Update Posted : February 27, 2013
Information provided by (Responsible Party):

Study Description
Brief Summary:
ALX-0171 is a Nanobody directed against the human respiratory syncytial virus (RSV). The purpose of this first-in-man study is to determine the safety, tolerability and pharmacokinetics (PK) of ALX-0171 after single and multiple pulmonary administrations in healthy male volunteers.

Condition or disease Intervention/treatment Phase
RSV Infection Biological: ALX-0171 Biological: Placebo Phase 1

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Phase I, Single-centre, Randomised, Placebo-controlled, Double-blinded Study, With Single Ascending Dose and Multiple Dose at Maximum Tolerated Dose, Evaluating the Safety, Tolerability and Pharmacokinetics of ALX-0171, Administered by Pulmonary Inhalation, in Healthy Male Volunteers
Study Start Date : December 2011
Primary Completion Date : May 2012
Arms and Interventions

Arm Intervention/treatment
Experimental: ALX-0171 Biological: ALX-0171
Single or multiple ascending doses (2.1-210 mg), administered via pulmonary inhalation. Multiple dosing will consist of twice daily dosing on 5 consecutive days.
Placebo Comparator: Placebo Biological: Placebo
Single or multiple doses, administered via pulmonary inhalation. Multiple dosing will consist of twice daily dosing on 5 consecutive days.

Outcome Measures

Primary Outcome Measures :
  1. number of treatment-emergent adverse events [ Time Frame: until 1 month after last study drug administration ]

Secondary Outcome Measures :
  1. plasma concentration of ALX-0171 [ Time Frame: from predose until 5 days after study drug administration ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Non-smoking healthy male volunteers, aged 18-55 years
  • Good health condition, as determined by medical history, physical examination and clinical laboratory testing
  • Forced expiratory volume in 1 second (FEV1) ≥ 90% of predicted value
  • Diffusing capacity of the lung for CO (DLCO) ≥ 85% of predicted value
  • Normal chest X-Ray (anteroposterior and lateral view)
  • Minimum weight of 70.0 kg, minimum height of 1m70, body mass index between 18.0 and 30.0 kg/m²

Exclusion Criteria:

  • Current smokers, or ex-smokers abstinent from tobacco for less than one year
  • History or presence of atopy or pulmonary non-specific hyperreactivity
  • Positive bronchial challenge test
  • Symptomatic viral infection, or suspicion thereof (including rhinitis) in last 14 days prior to dosing
  • Signs of active pulmonary infection or other inflammatory conditions, even in the absence of febrile episodes, in the last 14 days prior to dosing
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01483911

Groningen, Netherlands
Sponsors and Collaborators
Study Director: Josefin-Beate Holz, MD Ablynx
More Information

Responsible Party: Ablynx
ClinicalTrials.gov Identifier: NCT01483911     History of Changes
Other Study ID Numbers: ALX-0171-1.1/11
First Posted: December 2, 2011    Key Record Dates
Last Update Posted: February 27, 2013
Last Verified: October 2012

Additional relevant MeSH terms:
Respiratory Syncytial Virus Infections
Pneumovirus Infections
Paramyxoviridae Infections
Mononegavirales Infections
RNA Virus Infections
Virus Diseases